Core Viewpoint - Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for the active pharmaceutical ingredient (API) Sulfate Isavuconazole, indicating compliance with domestic drug registration requirements and enabling market sales in China [1] Group 1: Company Developments - The approval of Sulfate Isavuconazole API signifies that the product meets the necessary regulations for drug registration in China [1] - This achievement provides valuable experience for the company in future API submissions [1] - The current approval is not expected to have a significant impact on the company's operating performance for the period [1]

Core Viewpoint - Shanghai Pharmaceuticals announced the approval of the active pharmaceutical ingredient Sulfate Isavuconazole for production by its subsidiary, Upjohn Kangli (Changzhou) Pharmaceutical Co., Ltd, by the National Medical Products Administration of China [1] Group 1: Company Information - The approved drug, Sulfate Isavuconazole, is a triazole antifungal agent and a prodrug of Isavuconazole, which is rapidly converted into its active metabolite in the body by plasma esterases [1] - The drug is developed in collaboration with Astellas Pharma and Basilea Pharmaceutica, and it was approved for use in the United States in 2015 for the treatment of invasive aspergillosis and mucormycosis in adults [1] Group 2: Industry Context - Isavuconazole works by inhibiting the biosynthesis of ergosterol, thereby disrupting the formation of fungal cell membranes, similar to other triazole antifungal agents [1]

Group 1 - Shoukai Co. achieved a signed area of 125.72 million square meters and a signed amount of 17.845 billion yuan in 2025 [1] - Tongda Hai expects a net loss for the year 2025 [2] - Jiuri New Materials' subsidiary has entered the trial production phase for a project with an annual capacity of 350 tons of hydroxy ketone [3] Group 2 - Jixin Technology's shareholder plans to reduce their stake by up to 1% [4] - Fulai New Materials received approval from the CSRC for a stock issuance [5] - Yaqi International plans to sign a strategic cooperation framework agreement with Zhongnong Holdings [6] Group 3 - Sanwei Co.'s controlling shareholder plans to transfer up to 5.10% of shares [7] - Lekai Film's subsidiary plans to invest 97.6675 million yuan in a TAC functional film production line [8] - China Power Construction's subsidiary signed two major contracts totaling approximately 15.589 billion yuan [9] Group 4 - Shunhao Co. plans to increase its investment in a subsidiary by 74.98 million yuan [10] - Jieneng Wind Power reported a cumulative power generation of 12.417 billion kWh in 2025, a year-on-year increase of 1.43% [11] - Zhongjian Technology's H-share issuance application has been accepted by the CSRC [12] Group 5 - Hendi Pharmaceutical expects a net profit decrease of 57.4% to 66.14% in 2025 [13] - Haopeng Technology anticipates a net profit increase of 113.69% to 141.09% in 2025 [14] - Lingang Co. expects a net loss of 1.45 billion to 1.67 billion yuan in 2025 [15] Group 6 - Chuan Investment Energy reported a cumulative power generation of 6.627 billion kWh in 2025, a year-on-year increase of 13.85% [16] - Tengyuan Cobalt expects a net profit increase of 50.02% to 69.87% in 2025 [17] - Huazhi Jie plans to repurchase shares worth 30 million to 50 million yuan [18] Group 7 - Opto has won a bid for a 120 million yuan project from GoerTek [19] - Shanghai Construction reported a new contract amount of 252.942 billion yuan in 2025, a year-on-year decrease of 34.98% [20] - Hangfa Control expects a net profit decrease of 52.02% to 58.02% in 2025 [22] Group 8 - Shimao Energy is planning a change in control and will continue to suspend trading [23] - Shenwan Hongyuan Securities received approval for a bond issuance of up to 60 billion yuan [24] - Jingjiawei signed a strategic cooperation letter of intent with Jing'an Technology [25] Group 9 - Pianzaihuang completed the first subject enrollment for a clinical trial of a new drug [26] - Placo's subsidiary received a new veterinary drug registration certificate [27] - Zhongli Co. plans to reduce its stake by up to 0.75% [28] Group 10 - Solar Energy received renewable energy subsidies of 3.318 billion yuan in 2025, a year-on-year increase of 142.9% [29] - Palm Co. has filed a lawsuit to recover 144 million yuan in project payments [30][31] - Yongjin Co. plans to invest 2.658 billion yuan in a new stainless steel project [32] Group 11 - BAIC Blue Valley plans to increase its stake by 14.5 million to 16.4 million yuan [33] - Lingyun Light's stock issuance application has been approved by the CSRC [34] - Hongbo New Materials expects a net loss in 2025 [35] Group 12 - Shanghai Pharmaceuticals received approval for the listing of a new antifungal drug [36] - Changjiang Electric reported a net profit of 34.167 billion yuan in 2025, a year-on-year increase of 5.14% [37] - Weilan Bio received a new veterinary drug registration certificate [38] Group 13 - Pingzhi Information's subsidiary is expected to win a procurement project worth approximately 37.5884 million yuan [39]

Core Viewpoint - Shanghai Pharmaceuticals has received approval from the National Medical Products Administration for the production of the active pharmaceutical ingredient Isavuconazole sulfate [1] Group 1 - Shanghai Pharmaceuticals Group Co., Ltd. has announced that its subsidiary, Shanghai Pharmaceuticals Kangli (Changzhou) Pharmaceutical Co., Ltd., has obtained the approval notice for the listing application of Isavuconazole sulfate [1] - The approval is indicated by the certificate number 2025YS01127, allowing the company to commence production of the drug [1]

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司關於硫酸艾沙康唑原料藥上市申請獲得批准的公告》僅 供參閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2026 年 1 月 14 日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明 先生；非執行董事為張文學先生；以及獨立非執行董事為顧朝陽先生、霍文遜先 生、王忠先生及萬鈞女士。 * 僅供識別 一、该药物基本情况 名称：硫酸艾 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因依賴該等內容而引致之任何損失承擔任何責任。 ( 於中華人民共和國註冊成立的股份有限公司 ) * 僅供識別 (股份代碼: 02607) 1 關連交易最新進展 完成收購財務公司 10%股權 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2026年1月14日 上海醫藥集團股份有限公司 Shanghai Pharmaceuticals Holding Co., Ltd.* 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明先生；非 執行董事為張文學先生；以及獨立非執行董事為顧朝陽先生、霍文遜先生、王忠先生及萬 鈞女士。 茲提述上海醫藥集團股份有限公司（「本公司」）日期為2025年7月26日及2025年9月9日的公 告（「該等公告」），內容有關本公司由上實東灘收購財務公司10%股權（「本次收 購」）。除另有界定外，本公告所用詞彙與該等公告所界定者具有相同涵義。 本公司欣然宣佈於2026年1月12日，本次收購已依據該等公 ...

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Pharmaceuticals Kangli (Changzhou) Pharmaceutical Co., Ltd., received the approval notice from the National Medical Products Administration for the production of Sulfate Isavuconazole active pharmaceutical ingredient [1] Group 1: Company Information - The approved drug, Sulfate Isavuconazole, is a triazole antifungal medication and is a prodrug of Isavuconazole, which is rapidly converted into its active metabolite in the body by plasma esterases [1] - Isavuconazole, like other triazole antifungal drugs, works by inhibiting the biosynthesis of ergosterol, thereby disrupting the formation of fungal cell membranes [1]

关联/连交易的完成公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、交易概述 2025 年 7 月 25 日，上海医药集团股份有限公司（以下简称"公司"）第八 届董事会第二十三次会议审议通过了《关于收购上海上实集团财务有限公司 10% 股权暨关联/连交易的议案》，公司拟以自有资金约人民币 1.43 亿元收购上海实 业东滩投资开发（集团）有限公司（以下简称"上实东滩"）持有的上海上实集 团财务有限公司（以下简称"财务公司"）10%股权。 具体内容详见公司于 2025 年 7 月 26 日在上交所网站（http://www.sse.co m.cn/）披露的《上海医药集团股份有限公司关于收购上海上实集团财务有限公 司 10%股权暨关联/连交易的公告》（公告编号：临 2025-072）。 二、交易进展情况 截至 2026 年 1 月 12 日，公司与上实东滩、财务公司已共同申请办理并完成 股权变更登记手续，且公司已按照《股权转让协议》的约定向上实东滩一次性支 付全部股权转让对价，公司持有财务公司的股权比例由 30%增加至 ...

证券代码：601607 证券简称：上海医药 公告编号：临2026-003 上海医药集团股份有限公司 包装规格：1kg/桶，2kg/桶，5kg/桶，10kg/桶。 申请事项：境内生产化学原料药上市申请 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册。 二、该药物相关的信息 关于硫酸艾沙康唑原料药上市申请获得批准的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，上海医药集团股份有限公司（以下简称"上海医药"或"公司"）下 属上药康丽（常州）药业有限公司（以下简称"上药康丽"）收到国家药品监督 管理局（以下简称"国家药监局"）颁发的关于硫酸艾沙康唑原料药（以下简称 "该药物"）的《化学原料药上市申请批准通知书》（证书编号：2025YS01127）， 该药物获得批准生产。 一、该药物基本情况 名称：硫酸艾沙康唑 注册标准编号：YBY73682025 因受国家政策、市场环境等不确定因素影响，该药物可能存在销售不达预期 等情况，具有较大不确定性，敬请广大投资者谨慎决策 ...

Core Viewpoint - Shanghai Pharmaceuticals (601607) announced that its subsidiary, Shanghai Pharmaceuticals Kangli (Changzhou) Pharmaceutical Co., Ltd., received the approval notice from the National Medical Products Administration for the production of Sulfate Isavuconazole active pharmaceutical ingredient [1] Group 1 - The approved drug, Sulfate Isavuconazole, is a triazole antifungal medication [1] - Isavuconazole is a prodrug that is rapidly converted into its active metabolite, Isavuconazole, by plasma esterases in the body [1]